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Abstract
Considerable effort has been devoted to the development of strategies to reduce the incidence of
chronic lung disease, including use of medications, nutritional therapies, and respiratory care
practices. Unfortunately, most of these strategies have not been successful. To date, the only two
treatments developed specifically to prevent CLD whose efficacy is supported by evidence from
randomized, controlled trials are the parenteral administration of vitamin A and corticosteroids.
Two other therapies, the use of caffeine for the treatment of apnea of prematurity and aggressive
phototherapy for the treatment of hyperbilirubinemia were evaluated for the improvement of other
outcomes and found to reduce CLD. Cohort studies suggest that the use of CPAP as a strategy for
avoiding mechanical ventilation might also be beneficial. Other therapies reduce lung injury in
animal models but do not appear to reduce CLD in humans. The benefits of the efficacious
therapies have been modest, with an absolute risk reduction in the 7–11% range. Further
preventive strategies are needed to reduce the burden of this disease. However, each will need to
be tested in randomized, controlled trials, and the expectations of new therapies should be modest
reductions of the incidence of the disease.
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INTRODUCTION
After the development of chronic lung disease (CLD), medical care usually focuses on
utilizing respiratory therapies that minimize further lung injury and optimizing nutrition and
growth, with varying degrees of success. Therefore, because of the serious, long term health
consequences of CLD, considerable effort has been devoted to the prevention of the disease.
In this article, we examine the evidence of strategies that have been tested to prevent CLD.
CLD most often begins with early lung injury from respiratory distress syndrome (RDS).
Treatments that prevent or reduce the severity of RDS (e.g. surfactant replacement therapy)
were developed with the hope that they would reduce the likelihood of developing CLD.
Morbidities of prematurity, most notably persistent patency of the ductus arteriosus (PDA),
may contribute to CLD. Prevention or treatment of PDAs has been advocated as strategies to
prevent CLD. Various fluid and nutritional regimens have been utilized during the early
neonatal period because of their potential to modify the likelihood of developing CLD.
Finally, treatment of diseases or problems not related directly to the lungs (e.g. apnea of
prematurity) may have an impact on vulnerability to CLD. We review evidence primarily
NIH Public Access
Author Manuscript
Semin Fetal Neonatal Med. Author manuscript; available in PMC 2011 March 6.
Published in final edited form as:













from randomized, controlled trials (RCTs), or the combined results of trials in meta-
analyses, using the Cochrane Database of Systematic Reviews as the main source of
information. Although meta-analyses, including the Cochrane reviews, suffer from a number
of limitations, we believe that they provide the highest level of strength of evidence.1 2
TREATMENTS OF EARLY MORBIDITIES OF PREMATURITY
Surfactant Therapy
Following the development of exogenous surfactant preparations for the prevention and
treatment of RDS, there were expectations that the use of these products would decrease the
incidence of CLD. Surfactant therapy decreases mortality, particularly when used very soon
after birth as a prophylactic strategy (compared to treatment after established RDS) and also
reduces the incidence of lung injury as evidenced by a reduction in pneumothorax.3
Unfortunately, surfactant therapy does not however, reduce the incidence of CLD among
survivors.4–6
Since the original surfactant trials, two additional strategies of surfactant therapy have been
reported. The first method is to administer surfactant during a brief period of intubation
without obligatory mechanical ventilation (i.e. intubation, delivery of surfactant, and
immediate extubation).7 Benefits of this strategy have been reported in three trials.8–10
However, a statistical reduction in CLD was not observed in any of these trials. In a
Cochrane review, early surfactant treatment during a brief period of ventilation compared to
later selective surfactant therapy in ventilated infants resulted in a reduced incidence of air
leak and CLD (RR 0.51, 95% CI 0.26, 0.99), defined as oxygen therapy at 28 days.11
However, the more common definition of CLD, oxygen therapy at 36 weeks post-menstrual
age (PMA), could not be evaluated in this meta-analysis because it was not reported in all
trials. In a more recent trial, not included in the Cochrane review, very early surfactant
therapy administered in the delivery room without obligatory ventilation was demonstrated
to reduce the risk of mechanical ventilation.12 This study was not powered to examine CLD
at 36 weeks PMA, and there was no statistically significant improvement in CLD.
Another strategy is to administer surfactant beyond the first postnatal week to infants in
whom a secondary surfactant dysfunction may be present13, and whose risk for CLD is high.
In an RCT of surfactant therapy using this strategy, infants assigned to one of two doses of
surfactant had a lower mean fraction of inspired oxygen (33%) at twenty-four hours after
dosing, compared to infants assigned to the placebo group (39%).14 However, there was no
difference in the incidence of mortality or CLD between groups.
Conclusion—Surfactant replacement therapy is a standard of care for infants at risk for
RDS or with established disease based on reductions in mortality and air leak. However,
current evidence is insufficient to support alternate early surfactant treatment strategies (e.g.
treatment without obligatory mechanical ventilation) or treatment beyond the immediate
neonatal period for the prevention of CLD.
Closure of the Patent Ductus Arteriosus
Persistent patency of the ductus arteriosus (PDA) following preterm birth is common,
particularly among the least mature infants, and is associated with neonatal morbidities,
including CLD. 15 16 Shunting of blood from the systemic to pulmonary circulation may
have an effect on the mechanical properties of the lung, such as a decrease in lung
compliance 17 18, and these changes may provoke the need to increase ventilatory support.
This cascade of events may increase the likelihood of CLD by increasing ventilator-induced
lung injury.19 This hypothesis is supported by a strong association between the presence of a
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PDA and CLD. Although a causal relationship between a PDA and CLD has not been
established, many clinicians attempt to close PDAs under the assumption that early closure
decreases the likelihood of CLD and other morbidities.20
The Cochrane Reviews include two strategies to promote closure of PDAs: prophylactic
treatment with cyclo-oxygenase (COX) inhibitors of infants at risk for PDAs and treatment
with COX inhibitors of infants with asymptomatic PDAs identified by echocardiography.21
22 The review of prophylactic treatment with the COX inhibitor indomethacin suggests that
there are several short term benefits of this therapy, including a reduction in the incidence of
symptomatic PDA, serious intraventricular hemorrhage, and surgical ligation of PDAs.
However, despite improvements in these outcomes, the incidence of CLD is not reduced.23
Treatment with indomethacin of infants with asymptomatic PDAs appears to result in
similar benefits.22 There have been no reports of large, controlled trials of indomethacin for
the treatment of symptomatic PDAs conducted in the post-surfactant era. However, a
comprehensive report of older trials suggests a similar lack of reduction of CLD using this
strategy.24 Another COX inhibitor, ibuprofen, is as effective at promoting ductal closure, but
like indomethacin, does not appear to reduce mortality or the likelihood of CLD.25 Although
there have been no recent controlled trials comparing outcomes following ligation compared
to either placebo or medical therapy, a recent post-hoc analysis of an RCT of prophylactic
PDA ligation26 found that 48% of the infants allocated to prophylactic PDA ligation
developed CLD compared to 21% in the control group.27
This lack of demonstrable impact of ductal closure on the incidence of CLD may have
resulted, in part, from limitations imposed by study designs. Under the assumption that
closure of the PDA is beneficial, virtually all clinical trials in the modern era have focused
on the most expeditious way in which to close a PDA. None has addressed the more
fundamental question of whether closing the PDA improves outcome. Those trials that have
included control groups treated with a placebo have permitted treatment of a PDA that
persisted after reaching a defined study endpoint, often within days after enrollment. This
study design has resulted in high rates of treatment in the “placebo” group (usually in the
range of 40%) and has diminished the likelihood of identifying the effect of PDA closure on
other outcomes. Additionally, the ability to detect adverse effects of treatment is equally
compromised.
Conclusion—Evidence does not support the prevention or treatment of PDAs, with the
goal of closure, for the prevention of CLD.
Caffeine for Apnea of Prematurity
Caffeine is a methylxanthine used to treat apnea of prematurity. In a large RCT, the impact
of treatment with caffeine on neurodevelopmental outcome was tested in infants with birth
weights from 500 to 1250 g. Infants assigned to receive caffeine had a lower incidence of
neurodevelopmental impairment, most notably cerebral palsy (4.4% in the caffeine group vs.
7.3% in the placebo group) and cognitive delay (33.8% vs. 38.3%).28 One of the secondary
outcomes of the trial was CLD. Infants in the caffeine group had an incidence of CLD of
36% compared to 47% of infants placebo group (adjusted odds ratio [OR], 0.63; CI 0.52 to
0.76; p<0.001). The mechanism by which caffeine reduced the incidence of CLD is
uncertain. Positive airway pressure was discontinued one week earlier in the infants
receiving caffeine.29 Therefore, it is possible that caffeine reduced the exposure to
mechanical ventilation thereby reducing ventilator induced lung injury.
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Conclusion—Evidence supports the use of caffeine for the treatment of apnea of
prematurity in extremely low gestational age newborns, with the probability that a secondary
benefit will be a reduction of CLD.
Aggressive Phototherapy
Bilirubin is an efficient scavenger of oxygen and peroxyl radicals.30 Because oxidative
injury appears to be critical in the pathogenesis of CLD,31 bilirubin may have a protective
effect in the lung and decrease the likelihood of developing CLD. This possibility is
supported by observations from a single center retrospective study in which infants with
moderate and severe CLD had lower total bilirubin levels on the seventh postnatal day
compared to infants that did not develop CLD.32 However, in this study, infants with
moderate and severe CLD had lower birth weights, and adjustments were not made for these
differences or for exposure to phototherapy in the analyses. More definitive evidence about
the potential influence of bilirubin and phototherapy on the development of CLD is available
from a study in a large cohort of extremely low birth weight (ELBW; <1000 g birth weight)
infants designed to examine the effect of phototherapy on death and neurodevelopment. In
this study, infants were randomized either to aggressive phototherapy (starting at bilirubin
levels of 5 mg/dL for all infants) or to conservative phototherapy (bilirubin levels were
allowed to rise to 8 mg/dL for infants <750 g birth weight and 10 mg/dL for infants 751–
1000 g birth weight).33 There was no difference in mortality between the infants assigned to
aggressive phototherapy (21%) compared to those assigned to conservative phototherapy
(20%). Although CLD was not the primary outcome of the study, rates of CLD were
reported as a secondary outcome. Contrary to expectations based on the hypothesized role of
bilirubin in oxidative injury, the rate of CLD was significantly lower in the aggressive
phototherapy group compared to the conservative phototherapy group (41% vs 48%; OR
0.86, 95% CI 0.78–0.96).
Conclusion—Evidence supports the use of aggressive phototherapy in infants with birth
weights <1000 g, with the probability that a secondary benefit will be a reduction in CLD.
ANTI-INFLAMMATORY THERAPIES
Systemic corticosteroids: dexamethasone and hydrocortisone
Corticosteroids may affect pulmonary function and lung disease through several
mechanisms. Fetal exposure causes increased surfactant synthesis and lung epithelial
differentiation. In animals, early postnatal exposure causes increased surfactant synthesis.
However, their role in modulating lung inflammation is the primary mechanism through
which they may modify the likelihood of developing CLD.34 Corticosteroids decrease
recruitment of polymorphonuclear leukocytes to the lung, and reduce the production of
prostaglandins, leukotrienes, elastase and other inflammatory mediators, and decrease
vascular permeability and pulmonary edema formation. 34 Corticosteroids may also
modulate repair after lung injury by reducing fibronectin production, and subsequent
fibrosis, and increasing retinol concentrations (see Vitamin A below).
The use of corticosteroids for the prevention or treatment of CLD have been examined in
numerous clinical trials over the past 25 years. Most have demonstrated short-term
improvements in pulmonary function. Although these studies are not easily combined in
meta-analyses because of variability in study design, two Cochrane reviews provide
information about the effect of treatment with systemic steroids on the incidence of CLD.
The reviews differ based on the timing of treatment. Early treatment was defined as
beginning before eight postnatal days35; late treatment was defined as beginning after seven
days of postnatal age.36
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The review of early treatment examined 28 trials (20 used dexamethasone, 8 used
hydrocortisone) that enrolled 3740 infants. Benefits of early treatment included decreased
risks of CLD at both 28 days and at 36 weeks postmenstrual age (PMA) (RR 0.79, 95% CI
0.71, 0.88) and death or CLD at 28 days and at 36 weeks PMA (RR 0.89, 95% CI 0.84,
0.95). There were no differences in the incidence of mortality. Twelve trials examined the
neurodevelopmental impact of corticosteroids and demonstrated an increase in the risk of
cerebral palsy (RR 1.45, 95% CI 1.06, 1.98). The interpretation of neurodevelopmental
outcomes in these studies is challenging because of varying quality of assessment across
studies. However, impairment of motor function appears to be a risk associated with early
treatment.
The review of late treatment examined 19 trials that enrolled 1345 infants. Benefits of late
treatment included decreased risks of CLD at both 28 days and at 36 weeks PMA (RR 0.72,
95% CI 0.61, 0.85) and death or CLD at 28 days and at 36 weeks PMA (RR 0.72, 95% CI
0.63, 0.82). There was an increased risk of hyperglycemia, hypertension and hypertrophic
cardiomyopathy among treated infants. There was not an increased risk of blindness,
deafness, major neurosensory disability, or cerebral palsy. However, there was an increased
risk of abnormal neurological examination. The implications of this finding are unclear in
the absence of an increase in neurosensory impairment or cerebral palsy.
Given the concerns regarding the adverse effects of dexamethasone, hydrocortisone has
been examined separately as an alternative therapy to prevent CLD. Eight of the trials
reviewed in the Cochrane meta-analysis on early corticosteroids used hydrocortisone.35
Hydrocortisone had little effect on the incidence of CLD at 28 days or 36 weeks PMA (RR
0.96, 95% CI 0.82, 1.12) and there was an increased risk of gastrointestinal perforations (RR
2.02, 95% CI 1.13, 3.59). Early hydrocortisone was not associated with neurodevelopmental
impairment.
Although the risk of corticosteroid treatment for the prevention of CLD is not justified in all
premature infants, there may be some populations in which the benefits outweigh the harm
of this therapy. Doyle et al. suggest that the balance between benefit and risk may be
modified by baseline risk for CLD. 37 In a meta-regression analysis of previous RCTs of
corticosteroids, infants at high risk of developing CLD treated with corticosteroids were
shown to be more likely to survive without neurodevelopmental impairment. This study
suggested that a strategy of treatment would have net benefit if the risk for CLD of a
population reached a certain threshold. Presumably, the decrease in the risk of cerebral palsy
associated with CLD, by virtue of the beneficial effects of steroids in preventing CLD,
outweighs the increase in CP caused by steroids.
Conclusions—Evidence does not support the use of corticosteroids for the prevention of
CLD in populations of premature that include infants at relatively low risk of the disease.
Caution in the use of corticosteroids has been advised by the American Academy of
Pediatrics which recommends that systemic corticosteroids not be used outside the context
of a clinical trial.38 However, there may be populations with high baseline risk in which a
reduction in CLD would be accompanied by improved survival without neurodevelopment
impairment. Unfortunately, at this time, we do not have a mechanism for identifying these
populations. Therefore, any strategies for the use of corticosteroids for the prevention of
CLD would not be supported by evidence.
Inhaled corticosteroids
In addition to systemic therapy, corticosteroids may also be administered via an inhaler or,
more commonly, nebulization. Eleven trials were analyzed in a Cochrane review examining
the effect of early inhaled steroids beginning at less than two weeks postnatal age in
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ventilator- dependent infants on the incidence of CLD.39 There was no significant effect of
inhaled steroids on either CLD (RR 0.97, 95% CI 0.62, 1.52) or mortality. The use of
inhaled steroids for the prevention of CLD in infants not receiving mechanical ventilation
has not been evaluated.
Conclusion—Evidence does not support the use of inhaled corticosteroids for the
prevention of CLD.
Inhaled nitric oxide
Inhaled NO (iNO) improves oxygenation and reduces the need for extracorporeal membrane
oxygenation in term and near-term infants with respiratory failure from a variety of causes
including meconium aspiration syndrome, sepsis, and idiopathic persistent pulmonary
hypertension.40 Previous studies suggest that iNO can also improve gas exchange in
premature newborns with hypoxemia caused by the respiratory distress syndrome or
persistent pulmonary hypertension.41 iNO may also have anti-inflammatory properties. In
animal studies, iNO decreased early lung inflammation and oxidant stress,42 and improved
lung structure in models of CLD.43 These findings have stimulated the investigation of the
potential benefit of iNO in reducing the risk or severity of CLD in premature infants.
Interpreting the results of RCTs that examined the efficacy of iNO in the prevention of CLD
of these trials is challenging because of variability in study design, most notably variable
postnatal age of enrollment and baseline risk of CLD. Eleven RCTs of iNO therapy in
preterm infants were included in a Cochrane review44. To account for variation in study
design, the authors divided the trials into three categories based on entry criteria: 1)
enrollment during the first three postnatal days based on oxygenation criteria, 2) enrollment
of all intubated infants45 46, and 3) enrollment after the third postnatal day based on
increased risk of CLD.47 48 Only analyses of these subgroups were performed.
Trials of early treatment of infants enrolled based on oxygenation criteria demonstrated no
significant effect of iNO on mortality or CLD. Studies of iNO in intubated infants
demonstrated a marginally significant reduction in the combined outcome of death or CLD
(RR 0.91; 95% CI 0.84, 0.99). Late treatment based on the risk of CLD demonstrated no
reduction in death or CLD. However, one of the larger trials which enrolled intubated
infants during the second postnatal week demonstrated a reduction in CLD (50.7% in the
iNO group compared to 56.9% in the placebo group) but not death (5.4% vs. 6.3%).50
Conclusion—Evidence does not support a clear role for iNO for the prevention of CLD. It
is possible that certain populations defined by postnatal age and baseline risk may benefit,
but identifying these populations is not possible at this time.
Superoxide dismutase
Superoxide dismutase (SOD) is an enzyme that catalyzes the free oxygen radical superoxide
(O2−) into oxygen and hydrogen peroxide. Superoxide is toxic and promotes oxidative
damage in the lungs. 49 In a piglet model of acute lung injury caused by hyperoxia and
barotrauma, intratracheal administration of SOD improved lung compliance, and decreased
neutrophil chemotactic activity, total cell counts, and elastase activity recovered from
tracheal aspirates.49
SOD has been investigated in two RCTs to assess the effect of SOD in preventing CLD and
there was no reduction in CLD.50 51 However, one year follow-up in one trial demonstrated
that SOD might reduce the use of treatments with medications such as inhaled
corticosteroids and/or albuterol used to treat asthma.52
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Conclusion—Evidence does not support the use of SOD for the prevention of CLD.
Glutathione
Lung inflammation during mechanical ventilation, particularly with coincidental exposure to
high fractions of inspired oxygen, results in the generation of reactive oxygen species and
proinflammatory cytokines.53 These mediators may damage cells of the lungs and can
impair pulmonary development. Glutathione is an antioxidant that may inhibit some of these
changes. Quantities of glutathione are relatively deficient in preterm infants, and further
deficiency may occur because of limited availability of its precursor amino acid, cysteine.54
Supplementation of glutathione has been suggested as a strategy for minimizing the effects
of oxidatiove injury. Because glutathione does not readily cross cell membranes and
cysteine is unstable in solution, investigators have examined the ability of N-acetylcysteine,
a precursor to cysteine, to prevent CLD. In a multicenter RCT of 391 ELBW infants no
difference in CLD or death was observed between infants randomized to receive N-
acetylcysteine compared to placebo (51% vs. 49%).55 Levels of cysteine and glutathione
were actually lower among infants in the treatment group on days 3 and 7 of the study. This
finding may have resulted from the early administration of parenteral nutrition supplemented
with cysteine to both groups of infants.
Conclusion—Evidence does not support treatment with glutathione or its precursors for
the prevention of CLD.
OTHER MEDICATIONS
Vitamin A
Vitamin A derivatives define a group of fat soluble compounds called retinoids. These
compounds appear to play an important role in lung disease because they are critical in the
regulation and promotion of growth and differentiation of lung epithelial cells, particularly
during repair following lung injury.56 In animals, a deficiency of vitamin A results in
abnormal lung growth following prolonged exposure to hyperoxia.57 Preterm infants have
low vitamin A levels at birth, and low levels of vitamin A are associated with an increased
risk of CLD.58 Therefore, vitamin A supplementation was developed as a strategy for
preventing CLD.
In a Cochrane review, eight studies that examined the efficacy of vitamin A supplementation
in the prevention of CLD were identified. In ELBW infants, supplementation reduced the
incidence of CLD, defined as receipt of oxygen at 36 weeks PMA (RR 0.87, CI 0.77, 0.98),
with a number needed to treat of 13 (95% CI; 7, 100).59 In the largest study in the review,
among infants birth weight <1000 g, death or CLD was lower in the vitamin A group
compared to a placebo group (55% vs. 62% percent; RR, 0.89; 95 CI, 0.80 to 0.99).60
Neurodevelopment at 18 to 22 months of age was not different between groups.61
Conclusion—Evidence supports the use of vitamin A supplementation in infants with
birth weights <1000 g and meeting other eligibility requirements of the RCTs for the
prevention of CLD.
H2 blockers: cimetidine
Cimetidine is an H2 blocker that also inhibits cytochrome P450. Because upregulation of
cytochrome P450 may be important during lung injury, its inhibition may protective.
However, an RCT evaluating a 10 day infusion of cimetidine beginning in the first 24 hours
after birth in infants with birth weights <1250 g demonstrated no reduction in death or CLD
at 36 weeks PMA.62 No significant differences were identified for other earlier markers of
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pulmonary disease. The study was stopped after enrollment of 84 patients because of a
significant increase in death or severe intraventricular hemorrhage among infants receiving
cimetidine.
Conclusion—Evidence does not support treatment with cimetidine for the prevention of
CLD.
Treatment of Ureaplamsa with Macrolides
Although there is an association between colonization of the respiratory tract with
Ureaplasma and the development of CLD, a causal link between colonization and the
disease remains uncertain. In addition, treatments that both eradicate colonization and
reduce CLD remain elusive.63 For example, treatment of infants colonized with Ureaplasma
with erythromycin does not appear to reduce the incidence of CLD.64 Treatment with other
macrolides, such as azithromycin, have been investigated because these drugs also have
anti-inflammatory properties. However, in a small, single-center pilot study, azithromycin
therapy reduced the incidence of treatment with dexamethasone, but did not reduce the
incidence of CLD.65
Conclusion—Evidence does not support treatment of colonization of the respiratory tract
with Ureaplasma for the prevention of CLD. However, because of the strong association




Mechanical ventilation, although necessary for survival for many preterm infants, injures
lung tissue and is a risk factor for the development of CLD.66 After retrospective studies
indicated that higher levels of CO2 in the first few days of life were associated with lower
risk of CLD, 67 68 several investigators prospectively studied the practice of “permissive
hypercapnea”.69–71 The largest of these trials randomized 220 infants to a target PCO2 > 52
mm Hg (minimal ventilation) or < 48 mm Hg (routine care).70 No difference in the
incidence of CLD was observed, possibly because the separation of PCO2 between groups
was only 4.0 ± 1.3 mmHg. A similar finding of a small difference in PCO2 was
demonstrated in a subsequent study.69 A larger difference in PCO2 might have demonstrated
a difference in outcome. Although the practice of permissive hypercapnea has been widely
adopted, its contribution to reducing the overall burden of CLD is likely to be small if
benefits exists because of the pervasive practice and success of avoidance of ventilation.
Conclusions—Evidence is inconclusive that permissive hypercapnea is effective for the
prevention of CLD.
High Frequency Ventilation
Many clinicians use some form of high frequency ventilation (HFV), in lieu of conventional
mechanical (tidal) ventilation (CMV), in selected infants under the assumption that HFV is
less likely to induce lung injury. The mechanisms by which HFV might reduce lung injury
thereby decreasing the incidence of CLD include: 1) reducing regional lung overinflation; 2)
minimizing volutrauma; 3) minimizing pressure changes at the alveolar level, and 4)
lowering oxygen requirements.72–74 The initial large RCT comparing one form of HFV,
high frequency oscillatory ventilation (HFOV), to CMV was conducted in the pre-surfactant
era.75 This study found no difference in death or CLD between the HFOV and CMV groups,
but was criticized because of the manner in which HFOV was employed. A Cochrane
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review that includes 11 studies of HFOV compared to CMV, demonstrates a small decrease
in the relative risk of death or CLD at 36 weeks in infants treated with HFOV, (RR=0.90,
95% CI 0.83, 0.97).76 Subsequent studies of HFOV have yielded mixed results.77 78 Studies
of the impact on the incidence of CLD of two other methods of high frequency ventilation,
high frequency jet ventilation and the high frequency flow interrupter, are inconclusive.71
79–81
Conclusion—Current evidence does not support the routine use of HFV for the prevention
of CLD.
Continuous Positive Airway Pressure
The use of nasal continuous positive airway pressure (CPAP) appears to be a successful
strategy for avoiding the need for mechanical ventilation in some infants, with the
presumptive benefit of decreasing the risk of CLD.82 83 In an observational cohort study, an
association between the early use of nasal CPAP and decreased risk of CLD was reported84.
However, to date, a reduction in CLD has not been demonstrated in RCTs of early CPAP
compared to conventional ventilation. For example, in an RCT of 104 infants born <28
weeks gestation, infants receiving nasal CPAP in the delivery room had a rate of CLD
(29.4%) comparable to those treated with mechanical ventilation (27.9%), and more infants
treated with CPAP died (27% vs. 13%). 85 More recently, a larger RCT comparing the
initiation of nasal CPAP compared to intubation and mechanical ventilation in the delivery
room among 610 infants between 25 and 28 weeks gestation at birth.82 Although there was a
reduction in the combined outcome of death or oxygen requirement 28 days of age among
infants treated with early CPAP compared to those who were ventilated (OR; 0.63 [95%CI;
0.46, 0.88]), no difference was observed at 36 weeks PMA. These studies suggest that the
benefits reported in observational studies associated with the early CPAP as a strategy for
avoiding mechanical ventilation might be a marker for other center specific care practices
that have not been elucidated to date. A large trial in the National Institute of Child Health
and Human Development Neonatal Research Network comparing the use of nasal CPAP to
intubation and surfactant therapy has completed enrollment.86 Hopefully, the results of this
trial will help answer the unresolved questions about this potentially beneficial strategy.
Conclusion—Current evidence from RCTs does not support the routine use of CPAP to
avoid mechanical ventilation and to prevent CLD. However, the evidence in support of this
strategy from contemporary observational studies is compelling. It is seems likely that the
judicious use of CPAP immediately after birth, in lieu of mechanical ventilation or after a
brief period of ventilation, in carefully selected patient populations minimizes the likelihood
of developing CLD. This potential benefit may be augmented by a brief period of ventilation
for surfactant administration (see Surfactant Therapy above). However, the method for
selecting the population is not certain at this time.
NUTRITIONAL AND FLUID THERAPIES
Nutritional Support
The provision of the quality and quantity of energy substrates to premature infants may play
a role in the development of CLD. Premature infants may be vulnerable to the effects of
nutritional deprivation because they are born with lower glycogen stores and body fat
compared to term infants. Poor caloric intake during respiratory illness may result in
respiratory muscle fatigue and a longer duration of mechanical ventilation.87 In one case-
control study, infants that developed CLD had significantly lower mean energy intakes than
matched controls.88 In an unmasked RCT, 125 infants <1500 g birth weight were allocated
to either standard parenteral nutrition (maximum of 2 g/kg/day lipid, 2.5 mg/kg/day amino
Laughon et al. Page 9













acids, 10% dextrose solution, standard enteral feeding schedule) or aggressive nutrition
(maximum of 3.5 g/kg/day of lipids, 3.5 g/kg/day amino acids, 15% dextrose solution,
aggressive enteral feeding schedule). Infants in the aggressive nutrition cohort received
more caloric intake and experienced faster growth. However, pulmonary outcomes including
duration of mechanical ventilation, development of CLD (oxygen requirement at 28 days of
life), and need of oxygen at term were similar between groups. 89
Preterm infants are born with less fat and protein stores compared to infants born at term.
Lipids are normally administered as part of total parenteral nutrition in the first few
postnatal days. Polyunsaturated fatty acids can act as an antioxidant. Thus, in addition to
providing additional calories for growth, nutrition in the form of lipids that are high in
polyunsaturated fatty acids might protect the lung from oxygen toxicity.90 In a study
examining the potential benefits of early lipid supplementation, 183 ELBW infants were
randomized to lipid administration either beginning in the first 12 hours of life or after the
7th day of life, and the primary outcome was death or CLD.91 The study was stopped
because of a significant increase in mortality among the smallest infants (birth weights 600–
800 g) in the early lipid group. There was no difference between groups in the entire cohort
in the combined outcome of death or CLD.
Conclusion—There does not appear to be a nutritional strategy that decreases the
likelihood of developing CLD. A prudent approach would be to avoid malnutrition.
Fluid Restriction and Diuretic Therapy
Excessive lung water may interfere with respiration by impairing lung mechanics, and thus
increasing the need for oxygen and ventilatory support. By these mechanisms, excessive
lung water may play a role in the development of CLD. Extremely premature infants have a
relatively high percentage of body water that is largely in the extracellular fluid
compartment.92 The normal weight loss that occurs in the first few days after birth may not
occur if inappropriately large volumes of fluid are administered. Fluid restriction during this
critical period of time, therefore, may help prevent CLD. This possibility was examined in a
cohort of 1382 ELBW infants. Higher fluid intake and lack of weight loss during the first
postnatal week, even after adjustment for factors known to predict CLD, were associated
with a higher risk of death and CLD at 36 weeks PMA.93 A Cochrane review examined
restricted versus liberal water intake for preventing morbidity and mortality in preterm
infants and included 5 trials.94 The incidence of PDA and necrotizing enterocolitis was
lower in the restricted water intake groups. However, the risk of CLD was not different
between groups defined by water intake (RR 0.85, 95% CI 0.63 to 1.14).
Because sodium supplementation favors expansion of the extracellular fluid compartment,
early administration of sodium may also adversely affect risk of CLD. Forty-six infants were
randomized to either sodium supplementation after 6% weight loss following birth (delayed
supplementation) or supplementation beginning on the second day of life (early
supplementation). 95 Although there was a lower proportion of infants receiving oxygen at
28 days in the delayed sodium supplementation group, by 36 weeks PMA, there was no
difference in death or CLD in the early compared to the delayed group (54% vs 41%;
p=0.38).
Because pulmonary edema appears to be a prominent feature of CLD, diuretics are
commonly used to improve lung mechanics in infants with established disease. There is far
less experience with the use of diuretics early in life for the prevention of CLD. Two
Cochrane reviews examine the use of loop diuretics and diuretics acting on the distal renal
tubule.96 97 They include small studies of single dose or short course therapy and only report
short-term outcomes including: extubation rates, change in lung compliance, and change in
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fraction of inspired oxygen.98 99 The potential of these drugs for preventing CLD cannot be
determined from these studies.
Conclusion—An appropriate fractional loss of weight immediately after birth, compared
to persistence of excessive extracellular fluid, appears to decrease the likelihood of CLD.
Strategies for the administration of free water and sodium during the first week of life
should include this goal. Evidence does not support the use of diuretics to further decrease
exrtacellular fluid for the prevention of CLD.
QUALITY IMPROVEMENT TECHNIQUES
There has been considerable recent interest in using quality improvement or implementation
science methodologies to reduce morbidities associated with prematurity, including CLD.
This interest has been stimulated by the observation that there is great variability in
outcomes such as CLD among centers, even after adjustment for confounding risk factors
(e.g. birth weight distribution). The assumption is that variability in practice accounts for the
differences in outcome, and that uniform application of best practices would improve
outcomes in poorly performing centers. Reports of the success of these techniques in
reducing CLD have appeared in reports from single centers and use a before-after study
design. That is, the incidence of CLD is measured, an intervention or panel of interventions
is implemented, and the incidence of CLD is measured again.100 101 Using a similar, before-
after design to compare outcomes in 2001 to 2003, 19 hospitals in the Vermont-Oxford
Network reported a higher incidence of survival without CLD after initiation of a package of
potentially better practices (63.4% vs. 53.6%; OR 1.86; CI: 1.41–2.46).102 Hospitals used
conventional ventilation, postnatal steroids, and supplemental oxygen less frequently,
increased the use of nasal CPAP, and reduced the median time to first surfactant dose from
22 to 10 minutes after delivery after initiation of quality improvement techniques. In a study
using a cluster, randomized, controlled design, seven intervention centers received quality
improvement training including potentially better practices. The outcomes after this
intervention were compared to outcomes in seven control centers.103 Intervention centers
decreased the time of delivery of the first surfactant dose (from 51 minutes to 31 minutes),
increased the use of nasal CPAP on the first day (from 16.9% to 24.2%), and decreased the
duration of mechanical ventilation in the first week of life (from 4.0 ± 2.7 days to 3.5 ± 2.8
days). However, despite successful implementation of quality improvement techniques and
changes in these short-term outcomes, the rate of CLD was similar between the intervention
and the control centers (38.5% vs. 36.1%).
Conclusion
Incorporation of quality improvement methodology into clinical practice has vast potential
for improving outcomes and will unquestionably impact outcomes in neonatal medicine.
However, the paucity of evidenced-based practices for the prevention of CLD makes the
development of bundles of best practices, and therefore the application of quality
improvement methodology, difficult. Whether the utilization of these strategies can reduce
the incidence of CLD is as yet uncertain.
CONCLUSIONS
A variety of treatments have been used to prevent CLD, but only two medicinal therapies,
vitamin A supplementation and treatment with systemic corticosteroids, have proven
efficacy based on RCTs. Although not used specifically for the prevention of CLD, the
treatment of apnea of prematurity with caffeine and the use of aggressive phototherapy in
ELBW infants are also associated with reductions in CLD. Individually, these treatments
reduce risk by 7% to 11%. Unfortunately, treatment with systemic corticosteroids
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(particularly dexamethasone), although effective in reducing the risk of CLD, is associated
with increased rates of neurodevelopmental impairment. The benefits of treatment with
systemic corticosteroids may outweigh the risks in infants with high baseline risk of CLD.
The use of CPAP in selected populations of infants, in lieu of mechanical ventilation, may
also decrease the incidence of CLD, but further data is needed to define this population. The
use of quality improvement methodologies has potential for reducing CLD, but will rely
upon high quality evidence from RCTs that support bundles of best practices.
Because of the economic impact and long-term consequences of CLD, new preventive
therapies are desirable. Future trials that test these therapies should incorporate strategies to
systematically quantify the risk of CLD prior to enrollment. To date, a method for predicting
CLD with sufficiently high sensitivity and specificity has not been available. A new tool
using clinical and demographic variables appears promising.104 Because of the
heterogeneity of the causal pathways that lead to the development of CLD, it is unlikely that
a single preventive strategy will have a major impact on the reduction of CLD. Rather,
several strategies, with the expectation that each will contribute to a modest reduction in
CLD, will need to be tested in RCTs.
Practice Points
• CLD is an important morbidity associated with premature birth.
• The prevention strategies with the highest quality evidence with most favorable
benefit/risk ratio include vitamin A and caffeine.
• Corticosteroids reduce the incidence of CLD, but increase the risk of abnormal
neurologic examination.
Research Directions
• A simple, clinically relevant predictive model that objectively assesses the risk of
CLD needs to be developed.
• Well-powered trials of surfactant therapy with brief ventilation and later surfactant
therapy with the primary endpoint of CLD are needed.
• An RCT of systemic corticosteroids versus placebo among patients at high risk of
chronic lung disease is needed, with appropriate neurodevelopmental follow-up.
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